The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; AstraZeneca; Celldex; Eisai; Pfizer; Puma Biotechnology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Covance/Bayer (Inst); Incyte (Inst); Lilly (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).
 
Jame Abraham
Honoraria - Genentech/Roche; Pfizer
Speakers' Bureau - Pfizer
 
Shannon Puhalla
No Relationships to Disclose
 
William M. Sikov
Honoraria - Celgene; Eisai
Consulting or Advisory Role - Abbvie; Celgene
 
Alberto J. Montero
Stock and Other Ownership Interests - Johnson & Johnson
Honoraria - Celgene
Consulting or Advisory Role - New Century Health
 
Mohamad Adham Salkeni
No Relationships to Disclose
 
Wajeeha Razaq
No Relationships to Disclose
 
Jan Hendrik Beumer
Employment - Cardinal Health (I); GlaxoSmithKline (I); Voisin Consulting (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - BTG
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Millennium (Inst); Novartis (Inst); Saladax Biomedical (Inst); Spectrum Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Sulphoraphane for melanoma chemoprevention (Inst)
 
Brian Kiesel
No Relationships to Disclose
 
Marc E. Buyse
Employment - IDDI
Stock and Other Ownership Interests - IDDI
 
Laura M Adamson
No Relationships to Disclose
 
Ashok Srinivasan
No Relationships to Disclose
 
Katherine L. Pogue-Geile
Patents, Royalties, Other Intellectual Property - The following patent was submitted: U. S. Patent Application Serial No. 14/738,757, entitled: “Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin." Published 12/24/15.
 
Carmen Joseph Allegra
Honoraria - Bristol-Myers Squibb (I)
 
Samuel A. Jacobs
No Relationships to Disclose